Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2019

View Archived Issues

Anti-RSV agent ziresovir demonstrates promising preclinical profile

PDX model allows study of hepatitis B virus in hepatocellular carcinoma

Targeting NuRD for derepression of fetal hemoglobin in hemoglobinopathies

MSH3 linked to somatic expansion and disease phenotype in Huntington's disease and DM1

First patient enrolled in phase II study of AR-201 for egg allergy

MyoKardia initiates dosing in phase I study of MYK-224 for hypertrophic cardiomyopathy

Glenmark receives approval for combination of remogliflozin and metformin in India

Phase I data presented for CM-101 subcutaneous formulation

Shinkei Therapeutics files IND application with the FDA for MR-201

Discovery of novel antisense oligonucleotides for the treatment of prion disease

Discovery and preclinical evaluation of SH-379 as a novel anti-LOH agent

Results presented from phase III HOPE study of voxelotor in sickle cell disease

Eisai describes new aldehyde dehydrogenase-2 activators

Bruton tyrosine kinase inhibitors discovered at Merck & Co.

Pfizer identifies Gly12Cys mutant GTPase KRas inhibitors

Placental growth factor may be autoimmune disease target

Sichuan Kelun-Biotech Biopharmaceutical patents C-C chemokine receptor type 2/5 antagonists

Shenzhen Bo Li Jian Medicine discloses new mutant EGFR inhibitors

Japanese approval for Darzalex in newly diagnosed multiple myeloma

China's NMPA approves roxadustat for anemia in patients with CKD not receiving dialysis

Lonsurf approved in Japan for advanced gastric cancer

Could orphan opioid receptor prevent opioid orphans?

Identifying the cause of lupus cognitive dysfunction